Slow progressive degeneration of nigral dopaminergic neurons in postnatal Engrailed mutant mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 103, Issue 41, 2006, Pages 15242-15247

  Sgadò, Paola ^a   Albéri, Lavinia ^a   Gherbassi, Daniel ^a   Galasso, Sherri L ^c   Ramakers, Geert M J ^b   Alavian, Kambiz N ^a   Smidt, Marten P ^b   Dyck, Richard H ^c   Simon, Horst H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Dopamine; Midbrain; Mouse mutant; Neurodegenerative disease; Substantia nigra

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ENGRAILED 1; TRANSCRIPTION FACTOR ENGRAILED 2; UNCLASSIFIED DRUG;

AKINESIA; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; BRADYKINESIA; CAUDATE NUCLEUS; CELL SURVIVAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; GENETIC MODEL; GENETIC TRANSCRIPTION; HETEROZYGOSITY; HOMEOBOX; HOMOZYGOSITY; MOLECULAR BIOLOGY; MOTOR DYSFUNCTION; MOUSE; MOUSE MUTANT; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; NULL ALLELE; PARKINSON DISEASE; PERINATAL PERIOD; PHENOTYPE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; DOPAMINE; HOMEODOMAIN PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 33750061314     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0602116103     Document Type: Article

References (46)

1. Fallon JH, Loughlin SE (1994) in The Rat Nervous System, ed Paxinos G (Academic, London), pp 215-237.
2. Schultz W (2002) Neuron 36:241-263.
3. Girault JA, Greengard P (2004) Arch Neurol 61:641-644.
4. Eells JB (2003) Curr Med Chem 10:857-870.
5. Olanow CW, Tatton WG (1999) Annu Rev Neurosci 22:123-144.
6. Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller WC (1995) J Am Diet Assoc 95:979-983.
7. Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A (2003) Ann Neurol 53:676-679.
8. Alberi L, Sgadò P, Simon HH (2004) Development (Cambridge, UK) 131:3229-3236.
9. Simon HH, Saueressig H, Wurst W, Goulding MD, O'Leary DD (2001) J Neurosci 21:3126-3134.
10. Hanks M, Wurst W, Anson-Cartwright L, Auerbach AB, Joyner AL (1995) Science 269:679-682.
11. West MJ (1993) Neurobiol Aging 14:275-285.
12. German DC, Manaye KF (1993) J Comp Neurol 331:297-309.
13. Oo TF, Kholodilov N, Burke RE (2003) J Neurosci 23:5141-5148.
14. Simon HH, Thuret S, Alberi L (2004) Cell Tissue Res 318:53-61.
15. Burke RE, Antonelli M, Sulzer D (1998) J Neurochem 71:517-525.
16. Smidt MP, Asbreuk CH, Cox JJ, Chen H, Johnson RL, Burbach JP (2000) Nat Neurosci 3:337-341.
17. Smidt MP, Smits SM, Bouwmeester H, Hamers FP, Van Der Linden AJ, Hellemons AJ, Graw J, Burbach JP (2004) Development (Cambridge, UK) 131:1145-1155.
18. McCaffery P, Drager UC (1994) Proc Natl Acad Sci USA 91:7772-7776.
19. Saueressig H, Burrill J, Goulding M (1999) Development (Cambridge, UK) 126:4201-4212.
20. Davis CA, Joyner AL (1988) Genes Dev 2:1736-1744.
21. Davis CA, Holmyard DP, Millen KJ, Joyner AL (1991) Development (Cambridge, UK) 111:287-298.
22. Kawagoe KT, Zimmerman JB, Wightman RM (1993) J Neurosci Methods 48:225-240.
23. Gerfen CR (2000) Trends Neurosci 23:S64-S70.
24. Tillerson JL, Miller GW (2003) J Neurosci Methods 123:189-200.
25. Tillerson JL, Caudle WM, Reveron ME, Miller GW (2002) Exp Neurol 178:80-90.
26. Metz GA, Whishaw IQ (2002) J Neurosci Methods 115:169-179.
27. Fernagut PO, Diguet E, Labattu B, Tison F (2002) J Neurosci Methods 113:123-130.
28. Millen KJ, Wurst W, Herrup K, Joyner AL (1994) Development (Cambridge, UK) 120:695-706.
29. Gerlai R, Millen KJ, Herrup K, Fabien K, Joyner AL, Roder J (1996) Behav Neurosci 110:126-133.
30. Pfeiffer RF (2003) Lancet Neurol 2:107-116.
31. Macia F, Perlemoine C, Coman I, Guehl D, Burbaud P, Cuny E, Gin H, Rigalleau V, Tison F (2004) Mov Disord 19:206-212.
32. Barichella M, Marczewska AM, Mariani C, Landi A, Vairo A, Pezzoli G (2003) Mov Disord 18:1337-1340.
33. Gosgnach S, Lanuza GM, Butt SJ, Saueressig H, Zhang Y, Velasquez T, Riethmacher D, Callaway EM, Kiehn O, Goulding M (2006) Nature 440:215-219.
34. Simon HH, Scholz C, O'Leary DD (2005) Mol Cell Neurosci 28:96-105.
35. Blum M (1998) Nat Neurosci 1:374-377.
36. Roffler-Tarlov S, Martin B, Graybiel AM, Kauer JS (1996) J Neurosci 16:1819-1826.
37. Caspar P, Ben Jelloun N, Febvret A (1994) Neuroscience 61:293-305.
38. Harkins AB, Fox AP (2002) Cerebellum 1:201-206.
39. Dunnett SB, Bjorklund A (1999) Nature 399:A32-9.
40. Ricaurte GA, DeLanney LE, Irwin I, Langsten JW (1987) Neuropharmacology 26:97-99.
41. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) Brain 122 (Pt 8):1437-1448.
42. Dauer W, Przedborski S (2003) Neuron 39:889-909.
43. Joyner AL, Herrup K, Auerbach BA, Davis CA, Rossant J (1991) Science 251:1239-1243.
44. Wachtel SR, Bencsics C, Kang UJ (1997) J Neurochem 69:2055-2063.
45. Sutherland RJ, Dyck RH (1984) Can J Psychol 38:322.
46. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST (2000) Neuropharmacology 39:777-787.